Member Info for Laura2022

With Peters background you would think he could

Put PYC at forefront on UK cancer initiatives

 Sargent has also been Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK

I posted the last few paragraphs,I wonder if PYC A.I dosing tool found be innthe frame to help ?

https://www.dailymail.co.uk/health/article-13367687/amp/UK-prostate-cancer-trial-screening-programme-death-40.html?ico=amp_articleInlineText

The unreliability of the PSA test is why as yet, there is no national screening programme, despite 142 men a day in the UK being diagnosed with the disease.

Designed in consultation with the UK NSC and National Institute for Health and Care Research (NIHR), it is hoped the TRANSFORM trial will provide the evidence needed to get it over the line to join breast, cervical and bowel cancer screening.

Rakesh Heer, a clinician and Professor of Urology at Imperial College London who is also involved in the trial said: 'TRANSFORM is not only the most important diagnosis trial in more than two decades, but it could also prove a game changer for prostate cancer research as a whole.

'This treasure trove will help researchers around the world create and validate innovative new tests, treatments, and AI tools.'

Thanks itsagame

Upwards hard to buy this morning again

Just 200 shares ?

Hardly seems worth it (08.24am)

Maybe relates to this sentence ?

The Board of R&Q continues to evaluate any and all options to realise value from its legacy insurance business for the benefit of all its stakeholders, including its shareholders, whether that be through the ongoing trading of that business or through alternative strategic options.

Not sire what a special dividend means sorry??

Anyone else know plz ?

L

Agree with news

Seen an email of someone who has spoken to mgmt

With asset sale and de leveraging they are considering a large special dividend "significantly larger than the current market capitalisation '

The same as I saw it when I invested and added at 2p

Too dangerous holding past Tuesday 4 30pm

Know one knows

1) how many skeletons

2) terms of funding

Very impressive Ant

You really ARE convinced !!

Seems to be difficult to buy any real quantity again

Although I'd expect to hear something now the 2 conferences have finished

Isn't that an old one ?

Very wel done here

Not many IPOs have done as well as DARK, offer is 190%premium

As for ideas

Im biased as I've invested quite alot in PYC

They're the only AIM listed company that has the A.I tech to allow drug companies to specifically test their drugs pre FDA submissions

They have 30+main clients and growing

£1.8mlm cap with revenue's growing to £900k which should be enough for breakeven , pipeline grown 50% in 5mths to £1.5mln

A brilliant poster called Ant on there

Many thanks Ant

Very reassuring that someone with your expertise rates PYC

Also it clearly ststate'ONGÒING COMMITTMENTS"

Following closing of the Sale, the Board still intends to use the Available Net Cash Proceeds to facilitate a de-leveraging of R&Q while retaining liquidity and working capital for R&Q's ongoing commitments

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is delighted to announce that Merck & Co., a top 5 pharmaceutical company, has disclosed that it is a customer of Physiomics.   Merck & Co. published a paper in CPT: Pharmacometrics and Systems Biology (part of Nature Group) in which Virtual Tumour was specified as a technology which had helped their decision-making process

Debull

Nothing to apologise for as I had no idea pyc worked with both